Yixuan J. Hou

Yixuan J. Hou

Auto-generated profile, based on publicly available information

Yixuan J. Hou

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Cell
Verified
Journal Article
Closed access
YHYixuan J. Hou
Yixuan J. Hou
KOKenichi Okuda
Kenichi Okuda
CECaitlin E. Edwards
Caitlin E. Edwards
DMDavid R. Martinez
David R. Martinez
TATakanori Asakura
Takanori Asakura
RBRalph S. Baric
Ralph S. Baric

18 December 2020 in Science
Verified
Journal Article
Open access
PDF file
YHYixuan J. Hou
Yixuan J. Hou
SCShiho Chiba
Shiho Chiba
PHPeter Halfmann
Peter Halfmann
CECamille Ehre
Camille Ehre
MKMakoto Kuroda
Makoto Kuroda
RBRalph S. Baric
Ralph S. Baric
Changing with the times: Pandemic spread of a virus in naïe populations can select for mutations that alter pathogenesis, virulence, and/or transmissibility. The ancestral form of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged from China has now been largely replaced by strains containing the mutation D614G (Asp 614 -to-Gly) in the viral spike protein. Hou et al. compared the characteristics of the new variant against the ancestral form in a series of experiments in human cells and animal models. The variant is better at infecting upper-airway epithelial cells and replicates in greater numbers than the ancestral virus. Evidence indicates modest, if any, significant changes to virulence in animal models. Therefore, the virus appears to have evolved for greater transmissibility in humans rather than for greater pathogenicity. The mutation renders the new virus variant more susceptible to neutralizing antisera without altering the efficacy of vaccine candidates currently under development. Science , this issue p. 1464

27 August 2020 in Nature
Verified
Journal Article
Closed access
PDF file
KDKenneth H. Dinnon
Kenneth H. Dinnon
SLSarah R. Leist
Sarah R. Leist
ASAlexandra Schäfer
Alexandra Schäfer
CECaitlin E. Edwards
Caitlin E. Edwards
DMDavid R. Martinez
David R. Martinez
RBRalph S. Baric
Ralph S. Baric

1 October 2020 in Cell
Verified
Journal Article
Closed access
AHAhmed O. Hassan
Ahmed O. Hassan
NKNatasha M. Kafai
Natasha M. Kafai
IDIgor P. Dmitriev
Igor P. Dmitriev
JFJulie M. Fox
Julie M. Fox
BSBrittany K. Smith
Brittany K. Smith
MDMichael Diamond
Michael Diamond

1 December 2020 in Molecular Cell
Verified
Journal Article
Closed access
CIChristiane Iserman
Christiane Iserman
CRChristine A. Roden
Christine A. Roden
MBMark A. Boerneke
Mark A. Boerneke
RSRachel S.G. Sealfon
Rachel S.G. Sealfon
GMGrace A. McLaughlin
Grace A. McLaughlin
AGAmy S. Gladfelter
Amy S. Gladfelter

19 February 2021 in Science
Verified
Journal Article
Open access
PDF file
CRC. Garrett Rappazzo
C. Garrett Rappazzo
LTLong Ping Victor Tse
Long Ping Victor Tse
CKChengzi I. Kaku
Chengzi I. Kaku
DWDaniel Wrapp
Daniel Wrapp
MSMrunal Sakharkar
Mrunal Sakharkar
LWLaura M. Walker
Laura M. Walker
Targeting sarbecoviruses: As we continue to battle the COVID-19 pandemic, we must confront the possibility of new pathogenic coronaviruses emerging in humans in the future. With this in mind, Rappazzo et al. isolated antibodies from a survivor of the 2003 severe acute respiratory syndrome coronavirus (SARS-CoV), used yeast display libraries to introduce diversity into these antibodies, and then screened for binding to SARS-CoV-2. One of the affinity-matured progeny strongly neutralized SARS-CoV-2, SARS-CoV, and two SARS-related viruses from bats. In addition, this antibody bound to the receptor-binding domains from a panel of sarbecoviruses, suggesting broader activity, and provided protection against SARS-CoV and SARS-CoV-2 in mouse models. Science , this issue p. 823